
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For the Month of November, 2007

Commission File Number 1-32001

Lorus Therapeutics Inc.

(Translation of registrant's name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_____.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: November 19, 2007

By: /s/ "Elizabeth Williams"

Elizabeth Williams
Director of Finance

EXHIBIT INDEX

99.1 Lorus Therapeutics Inc. Annual and Special Meeting of Shareholders - Report on Proxies



**LORUS THERAPEUTICS INC.
ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
HELD ON SEPTEMBER 19, 2007**

REPORT ON PROXIES

MOTIONS	NUMBER OF SHARES					PERCENTAGE OF SHARES CAST		
	FOR	AGAINST	WITHHELD	SPOILED	NON VOTE	FOR	AGAINST	WITHHELD
Election of Directors	59,790,694	0	1,820,047	0	0	97.05%	0.00%	2.95%
Appointment of KPMG, LLP as auditors of the Corporation and authorizing the directors to fix their remuneration.	60,775,627	0	835,114	0	0	98.64%	0.00%	1.36%
To approve amendments to the 1993 and 2003 Stock Option Plans, as more particularly described under the heading "Amendment to 2003 Share Option Plan and 1993 Share Option Plan" in the Management Information Circular.	48,922,263	3,536,372	0	0	9,152,106	93.26%	6.74%	0.00%
To ratify and confirm the repeal of the Corporation's By-law No. 1 and the adoption of the Corporation's By-law No. 2 as set out in Schedule 1 to Appendix D of the Management Information Circular.	49,285,973	3,172,662	0	0	9,152,106	93.95%	6.05%	0.00%

TOTAL SHAREHOLDERS VOTED BY PROXY: 95
TOTAL SHARES ISSUED & OUTSTANDING: 212,627,866
TOTAL SHARES VOTED: 61,610,741
TOTAL % OF SHARES VOTED: 28.98%


 JAMIE BAJZIK
 SCRUTINEER


 FLORENCE SMITH
 SCRUTINEER